Buy Arymo ER 15 mg Online
Buy Arymo ER 15 mg Online (morphine sulfate) extended-release tablets are an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Do not attempt to chew, crush, or dissolve. Swallow whole.
• Use with caution in patients who have difficulty in swallowing or have
underlying GI disorders that may predispose them to obstruction, such
as a small gastrointestinal lumen.
Initial dose in opioid-naïve and opioid non-tolerant patients is 15 mg
every 8 or 12 hours
• Dosage adjustment may be done every 1 to 2 days.
• Take one tablet at a time, with enough water to ensure complete
swallowing immediately after placing in the mouth
SIDES EFFECTS
constipation,
nausea,
drowsiness,
dizziness,
vomiting,
sweating,
Indications for ARYMO ER:
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative therapies are inadequate.
Limitations of Use:
Not for use as an as-needed (prn) analgesic. Use only if alternative treatment options (eg, non-opioid analgesics, immediate-release opioids) are ineffective, not tolerated, or otherwise inadequate to provide sufficient management of pain.
Adult:
Use lowest effective dose for shortest duration. Swallow whole. Individualize. Opioid-naive or opioid non-tolerant: Initially 15mg every 8hrs or 12hrs. Dosage adjustments may be made every 1–2 days. Single dose >60mg or total daily dose >120mg: for use in opioid-tolerant patients only. Withdraw gradually by 25–50% every 2–4 days. Converting from other morphine formulations, other opioids: see full labeling.
Children:
<18yrs: not established.
Contraindications:
Significant respiratory depression. Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment. During or within 14 days of MAOIs. Known or suspected GI obstruction, including paralytic ileus.
Boxed Warning:
Addiction, abuse, and misuse. Risk evaluation and mitigation strategy (REMS). Life-threatening respiratory depression. Accidental ingestion. Neonatal opioid withdrawal syndrome. Risks from concomitant use with benzodiazepines or other CNS depressants.